Novo Nordisk A/S – Consensus Indicates Potential 1.5% Upside

Broker Ratings

Novo Nordisk A/S found using ticker (NVO) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 119.19 and 115.38 and has a mean target at 117.28. With the stocks previous close at 115.56 this indicates there is a potential upside of 1.5%. The 50 day moving average now sits at 102.48 and the 200 day MA is 91.49. The market capitalisation for the company is $265,043m. Find out more information at:

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson’s diseases; and bluebird bio to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  Novo Nordisk A/S - Consensus Indicates Potential 17.5% Upside

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index